Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer

Table 4 Levels of tumor markers in plasma of breast cancer patients and healthy controls.

Group	n	Median	Mean	S.D.	Lower-upper quartile	p-value
CEA (ng/ml)
healthy controls	58	1.13	1.62	1.46	0.84 – 1.75	0.04
cancer patients	37	1.54	2.45	3.11	1.00 – 2.11
CA15-3 (U/ml)
healthy controls	58	12.3	13.28	5.45	9.5 – 16.4	0.63
cancer patients	37	14.0	13.74	5.79	8.3 – 18.5
CYFRA 21.1 (ng/ml)
healthy controls	58	0.41	0.53	0.48	0.24 – 0.60	0.06
cancer patients	37	0.54	0.63	0.44	0.35 – 0.75
Leptin (ng/ml)
healthy controls	58	27.70	33.51	23.01	17.80 – 41.80	0.05
cancer patients	37	23.01	24.19	16.09	10.02 – 31.11
Osteopontin (ng/ml)
healthy controls	50	45.90	47.13	11.9	38.70 – 52.20	0.0003
cancer patients	73	54.73	59.47	15.37	47.13 – 66.98

Shown are median, mean and S.D. values, as well as lower and upper quartiles. The p-values are for differences between patients and healthy controls measured by the Kruskal-Wallis test.

ISSN: 1479-5876